The WSIB has a new policy on cannabis for treatment purposes coming into effect on March 1, 2019. The policy is quite restricted for a substance that can be obtained without a prescription for recreational use. It restricts medical cannabis to designated conditions where there is "strong and consistent evidence of a therapeutic effect" in light of the health risks. Medical cannabis for the purposes of the policy does not include pharmaceutical cannabinoids (CBD).
The designated conditions include:
1. neuropathic pain
2. spasticity resulting from a spinal cord injury
3. nausea and vomiting associated with cancer chemotherapy
4. loss of appetite associated with HIV or AIDS
5. pain and other symptoms experienced in a palliative setting
In all situations except a palliative setting, all "conventional" treatments must be exhausted, but conventional treatments may include pharmaceutical cannabinoids.
The policy can be accessed off the WSIB website.